Skip to main content

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes c, Andreu Vilaseca Jolonch, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 233750
Reference: PI24/01088
Duration: 01/01/2025 - 31/12/2027

Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias de remielinización en pacientes con esclerosis múltiple

IP: Andres Miguez Gonzalez
Collaborators: Gloria López Comellas, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140000
Reference: PI24/01117
Duration: 01/01/2025 - 31/12/2027

Human induced pluripotent stem cell-based chimeric mice to study astrocyte pathology and neuroprotective strategies in multiple sclerosis patients

IP: Manuel Comabella Lopez
Collaborators: Andres Miguez Gonzalez, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 286770
Reference: PI21/01611
Duration: 01/01/2022 - 30/06/2025

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...
Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

Related news

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Related professionals

Tao Gonzalez Zaragoza

Tao Gonzalez Zaragoza

Personal de manteniment i serveis generals
General Services and Infrastructures Unit
Infrastructure Coordination
Manager
Read more
Claudia Garcia-Arumí Fusté

Claudia Garcia-Arumí Fusté

Predoctoral researcher
Ophtalmology
Read more
Pere Canals Canals

Pere Canals Canals

Postdoctoral researcher
Stroke research
Read more
Margarita  Sanchez-Arcilla Rosanas

Margarita Sanchez-Arcilla Rosanas

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.